Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets

Thromb Haemost. 1991 Sep 2;66(3):300-5.

Abstract

The carboxy-terminal region of hirudin (residues 54-65) has previously been shown to inhibit thrombin clotting activity without binding to the catalytic site of the enzyme. In the present study, the effect of hirudin 54-65 on thrombin interaction with specified platelet proteins has been investigated. Hirudin 54-65 was found to inhibit thrombin-induced platelet aggregation and secretion in a dose-dependent manner. Substitution of either Phe56, Glu57, Ile59, Pro60 or Leu64 showed that these residues were critical for inhibition of thrombin-induced platelet activation whereas sulfation of Tyr63 increased the inhibitory potency of the peptide. Hydrolysis of glycoprotein V, a platelet membrane substrate for thrombin, was only partially inhibited by hirudin 54-65. Although hirudin 54-65 did not decrease the amount of thrombin bound to platelets during cross-linking experiments, it was found to inhibit the specific binding of thrombin to platelet glycoprotein Ib. Since the carboxy-terminal region of hirudin has previously been reported to bind near the trypsin-catalyzed beta cleavage site, we have analyzed the consequences of alpha to beta-thrombin conversion on both thrombin-hirudin 54-65 interaction and thrombin activity toward platelets. The beta cleavage induced a decrease in the affinity of thrombin for both glycoprotein Ib and hirudin 54-65. Altogether, our results indicate that thrombin recognition sites for hirudin 54-65 and platelet membrane glycoprotein Ib share common structures located near the beta cleavage site at Arg 73 on the thrombin B chain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Chymotrypsin
  • Hirudins / analogs & derivatives
  • Hirudins / chemistry
  • Hirudins / pharmacology*
  • Humans
  • Hydrolysis
  • Molecular Sequence Data
  • Peptide Fragments / pharmacology*
  • Platelet Activation / physiology
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Membrane Glycoproteins / metabolism
  • Protein Binding / drug effects
  • Thrombin / metabolism*

Substances

  • Hirudins
  • Peptide Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Membrane Glycoproteins
  • Chymotrypsin
  • Thrombin